Filing Flows › Opko Health (OPK) › R&D spending
Opko Health (OPK) R&D spending by quarter
Opko Health's R&D spending was $32.2M in Q3 2026 (third quarter 2026), -3% from Q2 2026. Over the last 6 quarters it ranged from $29.2M (Q1 2026) to $33.2M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $32.2M | -3% | — |
| Q2 2026 | $33.2M | +14% | +9% |
| Q1 2026 | $29.2M | -11% | -5% |
| Q4 2025 | $32.8M | +8% | — |
| Q2 2025 | $30.3M | -2% | — |
| Q1 2025 | $30.8M | — | — |
Q3 2026 at a glance
Opko Health, Q3 2026: revenue $65.4M (+16% year over year), operating margin -48.0%, net loss $53.5M, operating cash flow −$36.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Opko Health's R&D spending?
Opko Health's R&D spending was $32.2M in Q3 2026 (third quarter 2026), -3% from Q2 2026.
How has Opko Health's R&D spending changed?
Over the last 6 quarters it ranged from $29.2M (Q1 2026) to $33.2M (Q2 2026).